Skip to main content
Top

03-16-2018 | Type 2 diabetes | Article

Effect of screening for type 2 diabetes on healthcare costs: a register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009

Journal: Diabetologia

Authors: Camilla Sortsø, Anastasija Komkova, Annelli Sandbæk, Simon J. Griffin, Martha Emneus, Torsten Lauritzen, Rebecca K. Simmons

Publisher: Springer Berlin Heidelberg

share
SHARE

Abstract

Aims/hypothesis

Trials have not demonstrated benefits to the population of screening for type 2 diabetes. However, there may be cost savings for those found to have diabetes. We therefore aimed to compare healthcare costs among individuals with incident type 2 diabetes in a screened group with those in an unscreened group.

Methods

In this register-based, non-randomised controlled trial, eligible individuals were men and women aged 40–69 years without known diabetes who were registered with a general practice in Denmark (n = 1,912,392). Between 2001 and 2006, 153,107 individuals registered with 181 practices participating in the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care (ADDITION)-Denmark study were sent a diabetes risk-score questionnaire. Individuals with a moderate-to-high risk were invited to visit their family doctor for assessment of diabetes status and cardiovascular risk (screening group). The 1,759,285 individuals registered with all other practices in Denmark constituted the retrospectively constructed no-screening (control) group. In this post hoc analysis, we identified individuals from the screening and no-screening groups who were diagnosed with diabetes between 2001 and 2009 (n = 139,075). Using national registry data, we quantified the cost of healthcare services in these two groups between 2001 and 2012. From a healthcare sector perspective, we estimated the potential healthcare cost savings for individuals with diabetes that were attributable to the screening programme.

Results

In the screening group, 27,177 of 153,107 individuals (18% of those sent a risk-score questionnaire) attended for screening, 1533 of whom were diagnosed with diabetes. Between 2001 and 2009, 13,992 people were newly diagnosed with diabetes in the screening group (including those diagnosed by screening) and 125,083 in the no-screening group. Healthcare costs were significantly lower in the screening group compared with the no-screening group (difference in mean total annual healthcare costs −€889 per individual with incident diabetes; 95% CI −€1196, −€581). The screening programme was associated with a cost saving per person with incident diabetes over a 5-year period of €2688 (95% CI €1421, €3995).

Conclusions/interpretation

Healthcare costs were lower among individuals with incident type 2 diabetes in the screened group compared with the unscreened group. The relatively modest cost of screening per person discovered to have developed diabetes was offset within 2 years by savings in the healthcare system.
Literature
1.
Kahn R, Alperin P, Eddy D et al (2010) Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375:1365–1374 CrossRefPubMed
2.
Schuetz CA, Alperin P, Guda S et al (2013) A standardized vascular disease health check in europe: a cost-effectiveness analysis. PLoS One 8:e66454 CrossRefPubMedPubMedCentral
3.
Herman WH, Ye W, Griffin SJ et al (2015) Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care 38:1449–1455 CrossRefPubMedPubMedCentral
4.
Simmons RK, Echouffo-Tcheugui JB, Sharp SJ et al (2012) Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 380:1741–1748 CrossRefPubMedPubMedCentral
5.
Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A (2017) Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. Diabetologia 60:2183–2191 CrossRefPubMed
6.
Simmons RK, Griffin SJ, Lauritzen T, Sandbaek A (2017) Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia 60:2192–2199 CrossRefPubMed
7.
Lauritzen T, Griffin S, Borch-Johnsen K et al (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord J Int Assoc Study Obes 24(Suppl 3):S6–S11 CrossRef
8.
Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K (2004) Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 47:1566–1573 CrossRefPubMed
9.
Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156–167 CrossRefPubMedPubMedCentral
10.
Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K (2004) A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27:727–733 CrossRefPubMed
11.
Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003 CrossRefPubMed
12.
Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med J Br Diabet Assoc 15:539–553 CrossRef
13.
Carstensen B, Kristensen J, Ottosen P, Borch-Johnsen K (2008) The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 51:2187–2196 CrossRefPubMed
14.
Green A, Sortso C, Jensen PB, Emneus M (2015) Validation of the Danish National Diabetes Register. Clin Epidemiol 7:5–15 PubMed
15.
UNESCO (1997) International Standard Classification of Education 1997. United National Educational, Scientific and Cultural Organization, Paris
16.
Thygesen LC, Daasnes C, Thaulow I, Hansen HB (2011) Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation and archiving. Scand J Public Health 39(Suppl 7):12–16 CrossRefPubMed
17.
Dalsgaard EM, Christensen JO, Skriver MV, Borch-Johnsen K, Lauritzen T, Sandbaek A (2010) Comparison of different stepwise screening strategies for type 2 diabetes: finding from Danish general practice, ADDITION-DK. Prim Care Diabetes 4:223–229 CrossRefPubMed
18.
Drummond M, Sculper M, Torrance G, O’Brien B, Stoddart G (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, New York
19.
Ettaro L, Songer TJ, Zhang P, Engelgau MM (2004) Cost-of-illness studies in diabetes mellitus. PharmacoEconomics 22:149–164 CrossRefPubMed
20.
Bech M, Gyrd-Hansen D (2005) Effects coding in discrete choice experiments. Health Econ 14:1079–1083 CrossRefPubMed
21.
Sortsø C, Green A, Jensen P, Emneus M (2015) Societal costs of diabetes mellitus in Denmark. Diabet Med 33:877–885 CrossRefPubMedPubMedCentral
22.
Gillies CL, Lambert PC, Abrams KR et al (2008) Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 336:1180–1185 CrossRefPubMedPubMedCentral
23.
American Diabetes Association (2013) Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36:1033–1046 CrossRefPubMedCentral
24.
Zhong Y, Lin PJ, Cohen JT, Winn AN, Neumann PJ (2015) Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence. Value Health 18:308–314 CrossRefPubMed
25.
van Giessen A, Boonman-de Winter LJ, Rutten FH et al (2016) Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes. Cardiovasc Diabetol 15:48 CrossRefPubMedPubMedCentral
26.
Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C (2016) Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis. Dig Dis Sci 61:2108–2117 CrossRefPubMedPubMedCentral
27.
Neidell M, Lamster IB, Shearer B (2017) Cost-effectiveness of diabetes screening initiated through a dental visit. Community Dent Oral Epidemiol 45:275–280 CrossRefPubMed
28.
Ministeriet-sundhedogforebyggelse (2012) DRG-leksikon. Available from http://​www.​sum.​dk/​Sundhed/​DRG-systemet/​DRG-leksikon.​aspx. Accessed 30 April 2012
29.
Pedersen KM (2010) [DRG again again]. Ugeskr Laeger 172:2205 [article in Danish]
30.
Kristensen T, Rose Olsen K, Sortsø C, Ejersted C, Thomsen JL, Halling A (2013) Resources allocation and health care needs in diabetes care in Danish GP clinics. Health Policy 113:206–215